Src kinases as therapeutic targets for cancer

Nature Reviews Clinical Oncology

Volumn 6, Issue 10, 2009, Pages 587-595

  Kim, Lori C ^a   Song, Lanxi ^b   Haura, Eric B ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ACTIN; AP 23451; APP 22408; BOSUTINIB; CETUXIMAB; CRK ASSOCIATED SUBSTRATE PROTEIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FOCAL ADHESION KINASE; GEFITINIB; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INTEGRIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PAXILLIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; STAT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE METASTASIS; BREAST CANCER; CANCER INHIBITION; CANCER RELAPSE; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LOADING DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; METASTASIS; NAUSEA; NONHUMAN; OSTEOCLAST; OSTEOSARCOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RECTUM CANCER; RECURRENT CANCER; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; VOMITING;

ACTINS; ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; CRK-ASSOCIATED SUBSTRATE PROTEIN; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GTPASE-ACTIVATING PROTEINS; HUMANS; INTEGRINS; MAP KINASE SIGNALING SYSTEM; NEOPLASM METASTASIS; NEOPLASMS; PAXILLIN; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 70349758510     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.129     Document Type: Review

References (104)

1. Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397-411 (1911).
2. Martin, G. S. The hunting of the Src. Nat. Rev. Mol. Cell Biol. 2, 467-475 (2001).
3. Stehelin, D., Varmus, H. E., Bishop, J. M. & Vogt, P. K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260, 170-173 (1976).
4. Sadowski, I., Stone, J. C. & Pawson, T. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol. Cell Biol. 6, 4396-4408 (1986).
5. Mayer, B. J., Hamaguchi, M. & Hanafusa, H. A novel viral oncogene with structural similarity to phospholipase C. Nature 332, 272-275 (1988).
6. Xu, W., Harrison, S. C. & Eck, M. J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602 (1997).
7. Sicheri, F., Moarefi, I. & Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609 (1997).
8. Yeatman, T. J. A renaissance for SRC. Nat. Rev. Cancer 4, 470-480 (2004).
9. Irby, R. B. & Yeatman, T. J. Role of Src expression and activation in human cancer. Oncogene 19, 5636-5642 (2000).
10. Corey, S. J. & Anderson, S. M. Src-related protein tyrosine kinases in hematopoiesis. Blood 93, 1-14 (1999).
11. Finn, R. S. Targeting Src in breast cancer. Ann. Oncol. 19, 1379-1386; (2008).
12. Giaccone, G. & Zucali, P. A. Src as a potential therapeutic target in non-small-cell lung cancer. Ann. Oncol. 19, 1219-1223; (2008).
13. Yu, H. et al. Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science 258, 1665-1668 (1992).
14. Cartwright, C. A. et al. Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain. Cell 49, 83-91 (1987).
15. Yaffe, M. B. Phosphotyrosine-binding domains in signal transduction. Nat. Rev. Mol. Cell Biol. 3, 177-186 (2002).
16. Cowan-Jacob, S. W. et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13, 861-871 (2005).
17. Irby, R. B. et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21, 187-190 (1999).
18. Zheng, X. M., wang, Y. & Pallen, C. J. Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature 359, 336-339 (1992).
19. Brunton, V. G., MacPherson, I. R. & Frame, M. C. Cell adhesion receptors, tyrosine kinases and actin modulators: A complex three-way circuitry. Biochim. Biophys. Acta 1692, 121-144 (2004).
20. Sakai, T., Jove, R., Fassler, R. & Mosher, D. F. Role of the cytoplasmic tyrosines of beta 1A integrins in transformation by v-src. Proc. Natl Acad. Sci. USA 98, 3808-3813 (2001).
21. Datta, A., Huber, F. & Boettiger, D. Phosphorylation of beta3 integrin controls ligand binding strength. J. Biol. Chem. 277, 3943-3949 (2002).
22. Arthur, w. T. & Burridge, K. RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol. Biol. Cell 12, 2711-2720 (2001).
23. Hartsock, A. & Nelson, W. J. Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton. Biochim. Biophys. Acta 1778, 660-669 (2008).
24. Irby, R. B. & Yeatman, T. J. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res. 62, 2669-2674 (2002).
25. Behrens, J., Mareel, M. M., Van Roy, F. M. & Birchmeier, W. Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol. 108, 2435-2447 (1989).
26. Calautti, E. et al. Tyrosine phosphorylation and src family kinases control keratinocyte cell-cell adhesion. J. Cell Biol. 141, 1449-1465 (1998).
27. Reynolds, A. B., Roesel, D. J., Kanner, S. B. & Parsons, J. T. Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol. Cell Biol. 9, 629-638 (1989).
28. Reynolds, A. B. & Roczniak-Ferguson, A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 23, 7947-7956 (2004).
29. Timpson, P., Jones, G. E., Frame, M. C. & Brunton, V. G. Coordination of cell polarization and migration by the Rho family GTPases requires Src tyrosine kinase activity. Curr. Biol. 11, 1836-1846 (2001).
30. Hsia, D. A. et al. Differential regulation of cell motility and invasion by FAK. J. Cell Biol., 160, 753-767 (2003).
31. Siesser, P. M. & Hanks, S. K. The signaling and biological implications of FAK overexpression in cancer. Clin. Cancer Res. 12, 3233-3237 (2006).
32. Datta, K., Bellacosa, A., Chan, T. O. & Tsichlis, P. N. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. 271, 30835-30839 (1996).
33. Parsons, J. T. & Parsons, S. J. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr. Opin. Cell Biol. 9, 187-192 (1997).
34. Belsches, A. P., Haskell, M. D. & Parsons, S. J. Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front. Biosci. 2, d501-d518 (1997).
35. Biscardi, J. S., Ishizawar, R. C., Silva, C. M. & Parsons, S. J. Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2, 203-210 (2000).
36. Dimri, M. et al. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: C-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res. 67, 4164-4172 (2007).
37. Ishizawar, R. C., Miyake, T. & Parsons, S. J. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 26, 3503-3510 (2007).
38. Mori, S. et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J. 12, 2257-2264 (1993).
39. Kypta, R. M., Goldberg, Y., Ulug, E. T. & Courtneidge, S. A. Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell 62, 481-492 (1990).
40. Hansen, K. et al. Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J. 15, 5299-5313 (1996).
41. Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
42. Kanda, S., Miyata, Y., Kanetake, H. & Smithgall, T. E. Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int. J. Mol. Med. 20, 113-121 (2007).
43. Mukhopadhyay, D., Tsiokas, L. & Sukhatme, V. P. wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55, 6161-6165 (1995).
44. Eliceiri, B. P. et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol. 157, 149-160 (2002).
45. Xie, K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 12, 375-391 (2001).
46. Trevino, J. G. et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res. 65, 7214-7222 (2005).
47. Yeh, M. et al. Oxidized phospholipids increase interleukin 8 (IL-8) synthesis by activation of the c-src/signal transducers and activators of transcription (STAT)3 pathway. J. Biol. Chem. 279 30175-30181 (2004).
48. Petreaca, M. L., Yao, M., Liu, Y., Defea, K. & Martins-Green, M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol. Biol. Cell 18, 5014-5023 (2007).
49. Lesslie, D. P. et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br. J. Cancer 94, 1710-1717 (2006).
50. Kim, Y. M. et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J. Biol. Chem. 277, 6799-6805 (2002).
51. Hanke, J. H. et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271, 695-701 (1996).
52. Zhang, J. et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am. J. Pathol. 170, 366-376 (2007).
53. Kopetz, S., Shah, A. N. & Gallick, G. E. Src continues aging: Current and future clinical directions. Clin. Cancer Res. 13, 7232-7236 (2007).
54. Song, L., Turkson, J., Karras, J. G., Jove, R. & Haura, E. B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22, 4150-4165 (2003).
55. Niu, G. et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21, 7001-7010 (2002).
56. Malek, R. L. et al. Identification of Src transformation fingerprint in human colon cancer. Oncogene 21, 7256-7265 (2002).
57. Blake, R. A. et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell Biol. 20, 9018-9027 (2000).
58. 2+- dependent insulin release. Am. J. Physiol. Endocrinol. Metab. 292, E845-E852 (2007)
59. Nam, S. et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 65, 9185-9189 (2005).
60. Trevino, J. G. et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168, 962-972 (2006).
61. Song, L. et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 66, 5542-5548 (2006).
62. Shor, A. C. et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 67, 2800-2808 (2007).
63. Sen, B., Saigal, B., Parikh, N., Gallick, G. & Johnson, F. M. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 69, 1958-1965 (2009).
64. Herynk, M. H. et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol. Cancer Ther. 5, 3023-3031 (2006).
65. Hiscox, S., Morgan, L., Green, T. & Nicholson, R. I. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr. Relat. Cancer 13 (Suppl. 1), S53-S59 (2006).
66. Golas, J. M. et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63, 375-381 (2003).
67. Golas, J. M. et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 65, 5358-5364 (2005).
68. Coluccia, A. M. et al. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 66, 2279-2286 (2006).
69. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
70. Remsing Rix, L. L. et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23, 477-485 (2009).
71. Evans, T. R. et al. A dose-escalation study of SRC and multikinase inhibitor BMS-354825 in patients with GIST and other solid tumors (Abstract). J. Clin. Oncol. 23 (Suppl.), 3034 (2005).
72. Messersmith, W. A. et al. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase I study in patients with advanced malignant solid tumors [abstract]. ASCO Meeting Abstracts 25, a3552 (2007).
73. Tan, M. et al. ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res. 65, 1858-1867 (2005).
74. Knowlden, J. M. et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044 (2003).
75. Masaki, T. et al. pp60c-src activation in lung adenocarcinoma. Eur. J. Cancer 39, 1447-1455 (2003).
76. Kaplan, K. B., Swedlow, J. R., Morgan, D. O. & Varmus, H. E. c-Src enhances the spreading of src-/-fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev. 12, 1505-1517 (1995).
77. Hiscox, S. et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 97, 263-274 (2006).
78. Jallal. H, et al. Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 67, 1580-1588 (2007).
79. Mazurenko, N. N., Kogan, E. A., Zborovskaya, I. B. & Kisseljov, F. L. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer 28, 372-377 (1992).
80. Johnson, F. M., Saigal, B., Talpaz, M. & Donato, N. J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res. 11, 6924-6932 (2005).
81. Chiappori, A. A. et al. Phase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 26, a14605 (2008).
82. Migliaccio, A. et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res. 65, 10585-10593 (2005).
83. Yu, E. Y. et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study [abstract]. ASCO Meeting Abstracts 26, a5156 (2008).
84. Wainberg, Z. A. et al. Identification of predictive markers of response in colorectal cancer following treatment with dasatinib, an orally active tyrosine kinase inhibitor of ABL and SRC. ASCO Meeting Abstracts 26, a14688 (2008).
85. Koppikar, P. et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin. Cancer Res. 14, 4284-4291 (2008).
86. Grandis, J. R. & Tweardy, D. J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53, 3579-3584 (1993).
87. Temam, S. et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol. 25, 2164-2170 (2007).
88. Esteve, F. R. et al. Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies [abstract]. ASCO Meeting Abstracts 26, 14668 (2008).
89. Palacios, E. H. & weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23, 7990-8000 (2004).
90. Alvarez, R. H., Kantarjian, H. M. & Cortes, J. E. The role of Src in solid and hematologic malignancies: Development of new-generation Src inhibitors. Cancer 107, 1918-1929 (2006).
91. Danhauser-Riedl, S., Warmuth, M., Druker, B. J., Emmerich, B. & Hallek, M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 56, 3589-3596 (1996).
92. Ptasznik, A. et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J. Exp. Med. 196, 667-678 (2002).
93. Hu, Y. et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36, 453-461 (2004).
94. Donato, N. J. et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690-698 (2003).
95. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006).
96. Shah, N. et al. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL) [abstract]. ASCO Meeting Abstracts 23, a6521 (2005).
97. Miyazaki, T., Neff, L., Tanaka, S., Horne, W. C. & Baron, R. Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J. Cell Biol. 160, 709-718 (2003).
98. Lee, S. E. et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J. Biol. Chem. 276, 49343-49349 (2001).
99. Marzia, M. et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 151, 311-320 (2000).
100. Bakewell, S. J. et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc. Natl Acad. Sci. USA 100, 14205-14210 (2003).
101. Tabernero, J. et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. ASCO Meeting Abstracts 25, a3520 (2007).
102. Shakespeare, w. et al. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl Acad. Sci. USA 97 9373-9378 (2000).
103. Sawyer, T. et al. A new class of small-molecule therapeutics for osteolytic bone metastasis: Discovery of novel bone-targeted src tyrosine kinase inhibitors having potent in vitro and in vivo activities [abstract]. Proc. Am. Soc. Clin. Oncol. 22, a977 (2003).
104. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006).